Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial.

Chiong JR, Kim S, Lin J, Christian R, Dasta JF.

J Med Econ. 2012;15(2):276-84. doi: 10.3111/13696998.2011.643329. Epub 2011 Dec 8.

PMID:
22111754
3.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1332-43. Epub 2007 Mar 25.

PMID:
17384438
4.

Resource utilization in patients hospitalized with heart failure: insights from a contemporary national hospital database.

Hauptman PJ, Swindle J, Burroughs TE, Schnitzler MA.

Am Heart J. 2008 Jun;155(6):978-985.e1. doi: 10.1016/j.ahj.2008.01.015. Epub 2008 Mar 14.

PMID:
18513507
5.

Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in the US.

Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Lowe TJ.

J Med Econ. 2013;16(3):415-20. doi: 10.3111/13696998.2013.766615. Epub 2013 Jan 23.

PMID:
23336297
6.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1319-31. Epub 2007 Mar 25.

PMID:
17384437
7.

Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.

Raut M, Schein J, Mody S, Grant R, Benson C, Olson W.

Curr Med Res Opin. 2009 Sep;25(9):2151-7. doi: 10.1185/03007990903102743.

PMID:
19601711
8.

Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US.

Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Belk K, Baumer D, Lowe TJ.

J Hosp Med. 2012 Oct;7(8):634-9. doi: 10.1002/jhm.1973. Epub 2012 Sep 7.

PMID:
22961813
9.

Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis.

Deitelzweig S, Amin A, Christian R, Friend K, Lin J, Lowe TJ.

Adv Ther. 2013 Jan;30(1):71-80. doi: 10.1007/s12325-012-0073-1. Epub 2012 Dec 21.

PMID:
23292659
10.

Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.

de Lissovoy G, Fraeman K, Teerlink JR, Mullahy J, Salon J, Sterz R, Durtschi A, Padley RJ.

Eur J Health Econ. 2010 Apr;11(2):185-93. doi: 10.1007/s10198-009-0165-2. Epub 2009 Jul 7.

PMID:
19582491
11.

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.

Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE; Everest Investigators.

J Card Fail. 2013 Jun;19(6):390-7. doi: 10.1016/j.cardfail.2013.04.001. Epub 2013 May 14.

PMID:
23743487
12.
13.

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.

Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M; EVEREST Investigators.

J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8. doi: 10.1016/j.jacc.2008.07.056.

14.

Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).

Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA.

Am J Cardiol. 2012 Dec 15;110(12):1803-8. doi: 10.1016/j.amjcard.2012.08.016. Epub 2012 Sep 19.

PMID:
22999071
15.

Health care utilization, costs, and readmission rates associated with hyponatremia.

Deitelzweig S, Amin A, Christian R, Friend K, Lin J, Lowe TJ.

Hosp Pract (1995). 2013 Feb;41(1):89-95. doi: 10.3810/hp.2013.02.1014.

PMID:
23466971
16.

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.

Cardiovasc Drug Rev. 2007 Spring;25(1):1-13. Review.

PMID:
17445084
17.

Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.

Lee MY, Kang HJ, Park SY, Kim HL, Han E, Lee EK.

Clin Ther. 2014 Sep 1;36(9):1183-94. doi: 10.1016/j.clinthera.2014.07.010. Epub 2014 Aug 21.

PMID:
25151571
18.

EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.

Cavalcante JL, Khan S, Gheorghiade M.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1331-8. doi: 10.1586/14779072.6.10.1331.

PMID:
19018685
19.

An economic evaluation of perioperative adverse events associated with spinal surgery.

Hellsten EK, Hanbidge MA, Manos AN, Lewis SJ, Massicotte EM, Fehlings MG, Coyte PC, Rampersaud YR.

Spine J. 2013 Jan;13(1):44-53. doi: 10.1016/j.spinee.2013.01.003.

PMID:
23384882
20.

Update on tolvaptan for the treatment of hyponatremia.

Dasta JF, Chiong JR, Christian R, Friend K, Lingohr-Smith M, Lin J, Cassidy IB.

Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):399-410. doi: 10.1586/erp.12.30. Review.

PMID:
22971027
Items per page

Supplemental Content

Write to the Help Desk